These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Human leukocyte antigen and major histocompatibility complex class I-related chain A antibodies after kidney transplantation in Turkish renal transplant recipients. Seyhun Y; Ozdilli K; Oguz F; Karahan G; Onal E; Turkmen A; Eldegez U; Nane I; Çalişkan Y; Bakkaloglu H; Carin M Transplant Proc; 2012; 44(6):1660-6. PubMed ID: 22841239 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633 [TBL] [Abstract][Full Text] [Related]
4. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154 [TBL] [Abstract][Full Text] [Related]
5. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients. Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R Clin Transpl; 2014; ():215-21. PubMed ID: 26281148 [TBL] [Abstract][Full Text] [Related]
6. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503 [TBL] [Abstract][Full Text] [Related]
7. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts. Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999 [TBL] [Abstract][Full Text] [Related]
8. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study. Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731 [TBL] [Abstract][Full Text] [Related]
9. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation. Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991 [TBL] [Abstract][Full Text] [Related]
10. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Lee PC; Ozawa M Clin Transpl; 2007; ():219-26. PubMed ID: 18642453 [TBL] [Abstract][Full Text] [Related]
11. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604 [TBL] [Abstract][Full Text] [Related]
12. Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data. Ben Fredj N; Woillard JB; Debord J; Chaabane A; Boughattas N; Marquet P; Saint-Marcoux F; Aouam K Exp Clin Transplant; 2016 Aug; 14(4):394-400. PubMed ID: 27506258 [TBL] [Abstract][Full Text] [Related]
13. Early Intervention in Living Kidney Transplantation Based on Dynamic Monitoring of Donor Specific Antibodies. Chen Y; Li LY; Lou XY; Wang H; Zhang L; Zhu YH Clin Transpl; 2014; ():205-8. PubMed ID: 26281146 [TBL] [Abstract][Full Text] [Related]
15. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202 [TBL] [Abstract][Full Text] [Related]
17. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178 [TBL] [Abstract][Full Text] [Related]
18. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
19. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience. Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M Clin Transpl; 2011; ():373-9. PubMed ID: 22755434 [TBL] [Abstract][Full Text] [Related]
20. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Sapir-Pichhadze R; Wang Y; Famure O; Li Y; Kim SJ Kidney Int; 2014 Jun; 85(6):1404-11. PubMed ID: 24336032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]